Accelerating Cross-Sector Integration in Pharma and Nutraceuticals
Early-Phase Oncology Trials Shaping the Future of Cancer Research
Tailored Artificial Intelligence (AI)
Relatively Speaking
Cloud-Native Drug Discovery
EDITORIAL SECTION
-
STRATEGY
Smarter Pharma
Quality management systems QMS are the backbone of pharmaceutical manufacturing ensuring safe products
-
RESEARCH DEVELOPMENT
Cytiva Laboratory capsule filters
Our singleuse selfcontained filtration solution
-
CLINICAL TRIALS
Why Clinical Trials Need Digital Endpoints
According Citeline the average success rate for bringing a Phase candidate to market has dropped to an alltime low of just
-
MANUFACTURING
Ensuring Quality and Compliance in Biopharma
Ensuring quality and regulatory compliance in the biopharmaceutical industry is critical to safeguarding product safety and efficacy
-
Information Technology
The Cost of Bad Data
Modern pharmaceutical research generates an unprecedented volume of information Data from genomic sequencing
-
Biopharma
Reimagining Global Biomanufacturing Capacity with Continuous and Modular Systems
Biotechnology is fueling the ongoing expansion of the global market for a broad array of goods
-
EXPERT Talk
Compliance to Competitive Advantage in Pharma Supply
Compliance gets you through an audit Resilience gets medicines to patients on the day something unexpected happens The DSCSAs enhanced requirements took effect November but real interoperability required three more rounds of accommodation phased implementation with the smalldispenser
Advisory Board
.webp)
KNOWLEDGE BANK
-
Articles
Revolutionizing Biomanufacturing: Single-use Systems at the Forefront
In the rapidly evolving field of biomanufacturing singleuse systems have emerged as a gamechanger With their ability to optimize efficiency reduce contamination risks and lower costs these systems are revolutionizing the way biopharmaceuticals are produced
Acquisitions of Small-Medium Pharma Companies in EU
In EU the middleclass in Pharma is disappearing companies with revenues by M with a small factory and operations limited to some few countries
Multi-Omics Integration: Accelerating Precision Drug Development
The economics of pharmaceutical RD are dominated by a single line item that never appears on a balance sheet the programmes that did not work Only about one clinical programme in ten reaches approval and the cost of the nine that do not is carried entirely by the one that does
Artificial Intelligence in Pharmacy: A New Era of Drug Development and Personalized Care
Traditional pharmaceutical systems depend significantly on manual processes making drug development slow errorprone and inefficient New drug synthesis is a process that requires a lot of effort and time including stages such as lead compound identification and optimization and these are mostly done by trial and error The revolutionary development of artificial intelligence AI is that it can automa...
Unveiling the Revolutionary Potential: Exploring Blockchain Technology in Pharma
The pharmaceutical industry is renowned for its stringent regulations complex supply chains and crucial emphasis on data integrity In recent years the emergence of blockchain technology has sparked considerable interest
Pain Points and Progress: Navigating the Complexities of Life Sciences Logistics
Within recent years there has been a new facet of complexity in the supply chain pathways of the life sciences industry From rising geopolitical tensions to trade wars logistics teams now have to operate in an environment shaped by rapid change regulatory scrutiny and unpredictable policy changes influenced by politics
-
Techno Trends
Alume Biosciences Secures FDA Breakthrough Therapy Designation for Bevonescein
Alume Biosciences has received Breakthrough Therapy Designation BTD from the US Food and Drug Administration FDA for bevonescein an investigational fluorescent drug being developed to support realtime nerve visualisation during head and neck surgery in adults Bevonescein is an intravenous fluorescent peptidedye conjugate that binds to nerve tissue
-
Projects
SK pharmteco Plans More Than US$200 Million Investment in Small Molecule and Peptide Manufacturing
SK pharmteco is planning a fiveyear investment of more than US million to expand and modernise its pharmaceutical development and manufacturing operations in the United States The programme will strengthen capabilities for small molecules and peptides while supporting a more
-
Research Insights
A drug repurposing screen reveals dopamine signaling as a candidate therapeutic pathway for PIGA-CDG
PIGACDG is a congenital disorder of glycosylation caused by pathogenic partial lossoffunction variants in the PIGA gene PIGA encodes an enzyme responsible for the catalytic transfer of Nacetylglucosamine
-
whitepaper
Post-Translational Modifications in Drug Discovery: From Molecular Regulation to Clinical Impact
For decades the central dogma of molecular biology has anchored our understanding of cellular function DNA to RNA to protein But this linear view is incomplete A growing body of evidence shows that much of biologys
TOP ARTICLES
-
1
Acquisitions of Small-Medium Pharma Companies in EU
Angel Calvo Yague
In EU the “middle-class” in Pharma is disappearing; companies with revenues by 50 – 100 M€, with a small factory and operations limited to some few countries, belonging to a fam...
-
2
Multi-Omics Integration: Accelerating Precision Drug Development
Lakshmi
Roughly nine in ten clinical programmes fail, most often because the target was wrong. Multi-omics integration attacks that failure directly, asking whether independent molecular layers converge on th...
-
3
Artificial Intelligence in Pharmacy: A New Era of Drug Development and Personalized Care
Saisritam Kar
Dr. Vivek Dave
The world of the 21st century is experiencing an increasing burden of the rise of modern diseases and the rapid increase in the human population. The adaptability of Artificial intelligence (AI) provi...
-
4
Unveiling the Revolutionary Potential: Exploring Blockchain Technology in Pharma
Sarah Richards
This article explores the transformative potential of blockchain technology in the pharmaceutical industry, addressing challenges such as counterfeit drugs, supply chain inefficiencies, and data manag...
-
5
Pain Points and Progress: Navigating the Complexities of Life Sciences Logistics
Vincent Howard
Rising geopolitical tensions and trade wars are adding to the complexity in the life sciences supply chain. This article looks at how logistics teams are tackling these challenges, from geopolitical i...
press releases Read more...
NervGen Receives FDA Breakthrough Therapy Designation for NVG-291 in Chronic Spinal Cord Injury
NervGen NASDAQ NGEN a latestage clinical biopharmaceutical company developing firstinclass neuroreparative therapeutics for spinal cord injury SCI and other neurotraumatic and neurologic conditions today announced
Lineage Announces Acquisition of NeuroAirmid Therapeutics and Clinical Stage Program for the Treatment of Huntington’s Disease
Lineage Cell Therapeutics Inc NYSE American and TASE LCTX a clinicalstage biotechnology company developing allogeneic off the shelf cell therapies for serious medical conditions today announced that the Company has acquired NeuroAirmid
Instem and Sable Bio Launch Partnership to Accelerate Target Risk Assessment Through AI-Powered Scientific Intelligence
Instem a leading provider of software solutions and scientific services for drug discovery and development today announced a strategic partnership with Sable Bio to transform how biopharmaceutical organizations evaluate target safety and risk
Laboratoires Pierre Fabre and XtalPi Announce an AI-Driven Collaboration Focused on Drug Discovery
Laboratoires Pierre Fabre and XtalPi are pleased to announce an agreement under which they will collaborate on the discovery of novel clinical candidates across a number of research programs in the field of oncology potentially dermatology and rare diseases
Events Read more...
16 - 17
Nov 2026Analytics for Smarter Decisions in Pharma
London, UK
24 - 27
Nov 2026Pharmtech & Ingredients 2026
Crocus Expo, Pavilion 2, Mosco...
24 - 25
Nov 2026BioPharma Deals Conference 2026
Science Congress Center, Munic...
25 - 25
Nov 2026What’s Next for Pharma Marketing in 2027
Landesmuseum Zürich, Zurich, S...
26 - 28
Nov 2026One Health Conference 2026
Thapar Institute of Engineerin...
01 - 03
Dec 2026Pharmaceutical Launch Excellence Summit
Novotel Amsterdam City, Nether...
01 - 03
Dec 202610th Antifibrotic Drug Development
Boston, MA at the Hotel Common...
02 - 04
Dec 2026Genome Informatics 2026
Wellcome Genome Campus, UK
LATEST NEWS Read more...
Immuneering and Astellas to Evaluate Combination Treatments for CLDN18.2-Expressing Pancreatic Cancer
Immuneering Corporation Nasdaq IMRX has entered into a clinical trial collaboration and supply agreement with Astellas Pharma Global Development Inc a subsidiary of Astellas Pharma Inc TSE to evaluate combination treatments for patients with pancreatic cancer whose tumours express CLDN
Takeda Launches ORZEYFUL (Oveporexton), the First Orexin Agonist for Narcolepsy Type 1, in the US
Takeda TSE NYSE TAK has announced the US launch of ORZEYFUL oveporexton CIV now available by prescription for adults with narcolepsy type NT also known as narcolepsy with cataplexy The medicine is the first and only orexin agonist available for this condition
Applied Biologics Partners with Dartmouth College on Computational Protein Engineering Research
Applied Biologics a biopharmaceutical company developing biologic and gene therapies for serious diseases has entered into a research collaboration agreement with Dartmouth Colleges Thayer School of Engineering
Onco-Innovations Agrees to Terminate Performance-Based Funding Arrangement with Sorbie
OncoInnovations Limited Cboe ONCO has entered into an agreement with Sorbie Bornholm LP SBLP and Sorbie Investments LLP SILP to terminate its previously announced performancebased funding arrangement which was disclosed on July
Oncovita Granted Orphan Drug Designation For MVdeltaC in Mesothelioma by the European Commission
Oncovita a French biotechnology company specialized in therapeutic and prophylactic vaccines today announced that the European Commission has granted orphan medicinal product designation to its lead investigational candidate MVdeltaC for the treatment of mesothelioma
DeepLife and 3billion partner to discover small-molecule therapeutics against genetic modifier targets across multiple diseases
DeepLife a Parisbased techbio company developing AIpowered digital twins of human cells and billion an AIpowered genomics company specializing in rare disease diagnostics and drug discovery today announced a codevelopment collaboration to discover and develop new smallmolecule therapeutics
